<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454516</url>
  </required_header>
  <id_info>
    <org_study_id>FMRIMHM2018</org_study_id>
    <nct_id>NCT03454516</nct_id>
  </id_info>
  <brief_title>Mobility Hypertension Management Study</brief_title>
  <acronym>MHM</acronym>
  <official_title>Mobility Hypertension Management - Effect of Telemonitoring on Hypertension Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Society for Vascular Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Society for Vascular Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present prospective study aims to assess the efficacy of using the telehealth solution
      &quot;Hypertension Monitor&quot; in patients with hypertension by comparison to the standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although, meta-analysis confirms that BP telemonitoring may represent a useful tool to
      improve hypertension management, the strength of the provided evidence is limited. Therefore,
      future well-designed, large-sample, prospective, controlled trials are mandatory to
      understand the benefit of BP telemonitoring.

      Recently, a specific telehealth solution for hypertension management has been developed in
      France (Hypertension Monitor - e-CoreLab®).

      The present prospective study aims to assess the efficacy of using the telehealth solution
      &quot;Hypertension Monitor&quot; in patients with hypertension by comparison to the standard care.

      The primary objective: To evaluate whether a home telehealth system can improve BP control
      and other risk factors in hypertensive individuals, as compared to the standard care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two randomized parallel groups. one group with standard care and one group with telemonitoring of blood pressure and hypertension.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>the Data analysis will be performed by an independent team with masking the patients groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure (measured in clinic)</measure>
    <time_frame>Primary objective after 3 month</time_frame>
    <description>Systolic blood pressure will be measured in clinic according to the guidelines of the European Society of Hypertension (ESH).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing to reach the blood pressure target</measure>
    <time_frame>Evaluation performed at Month1 and Month 3</time_frame>
    <description>how long we need to reach the Blood pressure normalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group is the usual standard treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telemonitoring group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will followed up with telemonitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemonitoring</intervention_name>
    <description>the follow-up of the patient will be performed with Telemonitoring</description>
    <arm_group_label>Telemonitoring group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women

          -  Age between 18 and 80 years

          -  Patients with essential moderate Hypertension

          -  untreated or not adequately treated (need for treatment changes)

          -  Given written informed consent

        Exclusion Criteria:

          -  Severe Hypertension (&gt;180/110 mmHg)

          -  Difficulties to perform home blood pressure measurements

          -  Patients with arm circumference &gt; 42 cm

          -  Night shift workers

          -  Body mass index &gt; 35 kg/m²

          -  Atrial fibrillation and/or another arrhythmia

          -  Pregnancy

          -  Cardiovascular events (stroke, Myocardial infarction) in the last 6 months

          -  Severe Sleep Apnea Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROLAND ASMAR, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Foundation-Medical Research Institutes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROLAND ASMAR, MD</last_name>
    <phone>+33640142239</phone>
    <email>ra@cmcv.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roland Asmar</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROLAND ASMAR</last_name>
      <phone>640142239</phone>
      <email>ra@cmcv.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Telemonitoring</keyword>
  <keyword>Digital Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>the essential documents and the study results will be shared with all the investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Study documents: Q1 2018 Study Results: Q2 2019</ipd_time_frame>
    <ipd_access_criteria>the request will be reviewed by the scientific committee. Requestors will be required to sign an access agreement</ipd_access_criteria>
    <ipd_url>https://e-corelab.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

